Drug Profile
Research programme: anticancer therapeutics - OncoTartis
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator OncoTartis
- Class Antineoplastics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Breast-cancer in USA
- 28 Sep 2020 No recent reports of development identified for research development in Malignant-melanoma in USA
- 28 Sep 2020 No recent reports of development identified for research development in Ovarian-cancer in USA